Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "BioPharma-Reporter" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about BioPharma-Reporter for you to read. Along with our medical data and news we also list BioPharma-Reporter Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharma-Reporter Companies for you to search.
Catalent has cited Cook’s ability to make and freeze-dry liquid drugs as major drivers for its planned takeover and said it is keen to take on the firm’s biopharma customers.
Lonza has launched an updated version of its cell imaging technology, which it says has improved image capture and data transfer options, and enables researchers to monitor cells remotely.
Kiadis Pharma says it is looking at expanding production of its blood cancer cell therapy candidate ATIR101 after receiving US FDA breakthrough designation.
Pfizer has accused J&J of restricting biosimilar uptake through uncompetitive practises in its efforts to maintain a monopoly for its bestselling mAb Remicade (infliximab).
ChromaTan will develop an integrated and continuous downstream purification platform through provisions in the 21st Century Cures Act to support manufacturing initiatives.
State legislation allowing unapproved stem cell treatments could undermine efforts by the US FDA to clampdown on unregistered clinics.
SGI-DNA has selected BioCat to distribute its protein expression platform Vmax Express, which it says is more rapid than traditional expression systems.
Researchers say compounds from fire ant venom could be used to develop psoriasis treatments which limit skin-thickening side effects.
Catalent Inc has announced it will buy Cook Pharmica for $950m (€792m) in cash to boost its high tech drug production business.
Samsung Bioepis will use contractors to make its candidate Herceptin biosimilar Ontruzant if it goes on to be approved in Europe.
Bayer has signed a deal to use Berkeley Lights’ automated biological workflow platform for cell line development and antibody discovery.
Moving to a larger facility will help Scottish firm Synpromics Ltd increase its gene control and cell line services presence, the firm says.
US regulators have approved Amgen Inc’s Mvasi (bevacizumab-awwb), a biosimilar version of Roche’s monoclonal antibody (mAb) cancer treatment Avastin (bevacizumab).
Fears of Remicade competition have not manifested in significant growth declines for Johnson & Johnson, but Pfizer says US payers and physicians are slowly getting comfortable with biosimilars.
Kaneka Eurogentec has announced plans to build a biopharmaceutical manufacturing facility in Seraing, Belgium.
Researchers at Brown University have developed a 3D printing technique which they say could be used to make cell cultures for biopharmaceutical production.
Momenta says flexibility built into its contract with WuXi Biologics will offset fluctuations in demand for Chinese biosimilars.
Fujifilm Diosynth Biotechnologies has opened a $9m process development laboratory in Teeside, UK.
Biocon says its insulin plant in Malaysia has been awarded a European GMP certificate after an inspection by Ireland’s Health Products Regulatory Authority (HPRA).
Is plastic fantastic? Is stainless still à la mode*? Do Chinese hamsters continue to tow the cell line? Biopharma-Reporter wants your opinions for its second annual biomanufacturing survey.
Merck & Co has announced it will acquire immunotherapy-focused Rigontec and lead candidate RGT100, designed to treat patients with solid tumours and lymphoma.
Firms that make therapies at the Cell and Gene Therapy Catapult facility in Stevenage, UK will track their products using tech provided by TrakCel.
Eli Lilly has announced a restructuring plan which will cut around 3,500 jobs but biomanufacturing will remain largely unaffected.
Celltrion Inc has received a FDA Form 483 with 12 observations but remains confident no exported biosimilar products have any quality issues.
GE Healthcare has launched a thawing technology for cell therapies it says removes the risks and inconsistencies of standard water baths.